BioSpace News Archive

Partnership Between Best-in-Class ACP Organizations Supports Person-Centered Care by Enabling Doctors and Nurses to Quickly Understand Patient Care Wishes

VolitionRx Limited, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has announced the launch of its first product, the Nu.Q™ Vet Cancer Screening Test.

Lore IO Inc., providers of an AI-powered common data model that enables faster vendor data onboarding and unified data views, today announced the immediate availability of Lore IO Life Sciences Cloud Analytics Packages,

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a Phase 2 clinical trial of CPI-613® (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue. In partnership with Sara’s Cure and Sarcoma Alliance for Research through Collaboration (SARC),

St. Croix Hospice, a Midwest leader in hospice care, announces its innovative new InTouch Family Connection Program.

VivaLNK, a leading provider of connected healthcare solutions known for its unique medical wearable sensor platform and vitals data service, announces today that Jennifer Esposito joins its Board of Directors.

Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions

Medical Technology Disruptors Panel includes Renovia’s leva® Digital Therapeutic, a novel approach for an underreported disorder affecting 20 million women in the U.S.

McKesson Ventures, the venture capital arm of McKesson Corporation, announces the expansion of its leadership team, welcoming Michelle Snyder as its newest investment partner.

Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the development of regenerative medicines to save lives, announced today that the Biomedical Advanced Research and Development Authority (BARDA) part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services executed options to add $10.4 million under contract # HH